Current Hepatitis Reports

, Volume 10, Issue 1, pp 19–26

Update on Current Epidemiologic Trends in Hepatitis C



Hepatitis C virus infection remains a leading cause of liver disease worldwide and is currently the principal reason for liver transplantation in the United States. Although the prevalence of hepatitis C has decreased, it remains the most common blood-borne infection, and simulation studies project rising disease burden that peaks in the next decade from hepatic complications in those with long-standing disease. Over the past few years, incidence rates have remained constant, emphasizing the need to understand more completely the natural history and epidemiology of acute disease to improve preventive and screening practices. Recent advances in knowledge about interactions between the virus and host genetics offer a glimpse into future genomic-based medical treatment. This review highlights current literature in hepatitis C epidemiology, focusing especially on preventable health care-related outbreaks, hepatitis B coinfection, and molecular epidemiology.


Hepatitis C Prevalence Incidence Epidemiology Risk factors Infection control Injections Equipment contamination Substance abuse 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74–81.CrossRefPubMedGoogle Scholar
  2. 2.
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.CrossRefPubMedGoogle Scholar
  3. 3.
    Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.CrossRefPubMedGoogle Scholar
  4. 4.
    • McQuillian GM, Kruszon-Moran D, Denniston MM, Hirsch R. Viral hepatitis. NCHS data brief. 2010:1-8. The most recent nationally representative US survey (2007–2008 NHANES) found that the prevalence of HCV at 1.3% has remained unchanged since 2003–2006, with the highest rates in non-Hispanic blacks and in 40 to 49 year olds.Google Scholar
  5. 5.
    •• Muhlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009;9:34. Summarizing the burden of HCV infection across 22 countries of the WHO European region, this systematic review estimated that 1.1% to 1.3% of these populations have HCV infection. It highlights the scarcity of available data and the need for additional resources to improve the data quality (eg, obtaining community-based studies as in the United States).CrossRefPubMedGoogle Scholar
  6. 6.
    Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Lehman EM, Wilson ML. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J Viral Hepat. 2009;16:650–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ. 2009;58:1–27.PubMedGoogle Scholar
  9. 9.
    IOM (Institute of Medicine). Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010.Google Scholar
  10. 10.
    Klevens RM, Miller J, Vonderwahl C, et al. Population-based surveillance for hepatitis C virus, United States, 2006–2007. Emerg Infect Dis. 2009;15:1499–502.CrossRefPubMedGoogle Scholar
  11. 11.
    Gidding HF, Topp L, Middleton M, et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology & Hepatology. 2009;24:1648–54.CrossRefGoogle Scholar
  12. 12.
    Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513–21, 521 e1–6.Google Scholar
  13. 13.
    Mariano A, Scalia Tomba G, Tosti ME, et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41:689–99.CrossRefPubMedGoogle Scholar
  14. 14.
    Razali K, Amin J, Dore GJ, et al. Modelling and calibration of the hepatitis C epidemic in Australia. Stat Methods Med Res. 2009;18:253–70.CrossRefPubMedGoogle Scholar
  15. 15.
    • David TL, Chloe TL, Maureen MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–802. Given the strong association of the IL28B gene with an increased response to HCV drug treatment, these researchers demonstrated the association of this same gene with spontaneous clearance of HCV and described the frequency of this allele globally.CrossRefGoogle Scholar
  16. 16.
    • Cox AL, Page K, Bruneau J, et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology. 2009;136:26–31. Multiple researchers demonstrate the feasibility of identifying individuals with acute hepatitis C, thereby creating opportunities to examine the initial host-virus interactions that lead to chronic infection in most individuals.CrossRefPubMedGoogle Scholar
  17. 17.
    Morin T, Pariente A, Lahmek P, et al. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol. 2010;22:157–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Deterding K, Wiegand J, Gruner N, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol. 2009;47:531–40.CrossRefPubMedGoogle Scholar
  19. 19.
    McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49:1051–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1–39.Google Scholar
  21. 21.
    Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82:546–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Shannon K, Kerr T, Marshall B, et al. Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a canadian setting. Arch Pediatr Adolesc Med. 2010;164:61–5.CrossRefPubMedGoogle Scholar
  23. 23.
    van den Berg CHSB, van de Laar TJW, Kok A, et al. Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. J Viral Hepat. 2009;16:568–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim C, Kerr T, Li K, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health. 2009;9:270.CrossRefPubMedGoogle Scholar
  25. 25.
    • Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion. 2010;50:1495–504. This study demonstrates that the introduction of NAT screening of donated blood has improved the safety of the US blood supply with the prevalence of HIV or HCV infection falling below 1 in a million. However, rising HIV and HCV incidence rates from 2007 to 2008 affirm the importance of continued monitoring.CrossRefPubMedGoogle Scholar
  26. 26.
    Shang H, Zhong P, Liu J, et al. High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS ONE. 2010;5:e10631.CrossRefPubMedGoogle Scholar
  27. 27.
    McDonald SA, Hutchinson SJ, Mills PR, et al. Diagnosis of hepatitis C virus infection in Scotland’s injecting drug user population. Epidemiol Infect. 2010;138:393–402.CrossRefPubMedGoogle Scholar
  28. 28.
    Hickman M, Hope V, Coleman B, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf). 2009;31:374–82.CrossRefGoogle Scholar
  29. 29.
    Jauffret-Roustide M, Le Strat Y, Couturier E, et al. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009;9:113.CrossRefPubMedGoogle Scholar
  30. 30.
    Platt L, Sutton AJ, Vickerman P, et al. Measuring risk of HIV and HCV among injecting drug users in the Russian Federation. Eur J Public Health. 2009;19:428–33.CrossRefPubMedGoogle Scholar
  31. 31.
    Roy E, Boudreau J-F, Boivin J-F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend. 2009;102:158–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Tweed E, Brant L, Hurrelle M, et al. Hepatitis C testing in sexual health services in England, 2002–7: results from sentinel surveillance. Sex Transm Infect. 2010;86:126–30.CrossRefPubMedGoogle Scholar
  33. 33.
    Centers for Disease Control and Prevention. Acute hepatitis C virus infections attributed to unsafe injection practices at an endoscopy clinic--Nevada, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:513–7.Google Scholar
  34. 34.
    •• Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998–2008. Ann Intern Med. 2009;150:33–9. By shining a bright light on non-hospital health-care associated acute viral hepatitis outbreaks occurring in the United States from 1998 through 2008, this epidemiologic investigation of HBV and HCV outbreaks suggests that adhering to basic infection control practices could have prevented all transmissions and warns that increasing outpatient care delivery could foster additional such outbreaks.PubMedGoogle Scholar
  35. 35.
    Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol. 2001;65:30–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang M, Fan J, Li H, et al. Alternative risk factors of HCV infection in a rural community in China. Epidemiol Infect. 2010;138:1032–5.CrossRefPubMedGoogle Scholar
  37. 37.
    Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C virus. J Hepatol. 2008;48:2–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Miller ER, Bi P, Ryan P. Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors. Int J Infect Dis. 2009;13:201–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Rosen DL, Schoenbach VJ, Wohl DA, et al. Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system. Am J Public Health. 2009;99:1123–30.CrossRefPubMedGoogle Scholar
  40. 40.
    Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51:759–66.PubMedGoogle Scholar
  41. 41.
    Sagnelli E, Coppola N, Pisaturo M, et al. HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV. Hepatology. 2009;49:1090–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Cho LY, Yang JJ, Ko KP, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis. Int J Cancer. 2010.Google Scholar
  43. 43.
    •• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401. This genome-wide association study of a randomized controlled trial of antiviral treatment describes the twofold change in treatment response associated with IL28B gene polymorphism in both African American and European American patients. The higher prevalence of the IL28B gene in those of European ancestry explains their higher response rates.CrossRefPubMedGoogle Scholar
  44. 44.
    Pybus OG, Barnes E, Taggart R, et al. Genetic history of hepatitis C virus in East Asia. J Virol. 2009;83:1071–82.CrossRefPubMedGoogle Scholar
  45. 45.
    Markov PV, Pepin J, Frost E, et al. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J Gen Virol. 2009;90:2086–96.CrossRefPubMedGoogle Scholar
  46. 46.
    de Bruijne J, Schinkel J, Prins M, et al. Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol. 2009;47:3832–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Lee Y-M, Lin H-J, Chen Y-J, et al. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w. J Med Virol. 2010;82:57–68.CrossRefPubMedGoogle Scholar
  48. 48.
    Brant LJ, Ramsay ME, Tweed E, et al. Planning for the healthcare burden of hepatitis C infection: Hepatitis C genotypes identified in England, 2002–2007. J Clin Virol. 2010;48:115–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Wand H, Spiegelman D, Law M, et al. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Addiction. 2009;104:2049–56.CrossRefPubMedGoogle Scholar
  50. 50.
    •• Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis. 2009;48:650–8. The Australian Trial in Acute Hepatitis C demonstrates the feasibility and effectiveness of identifying and treating recent HCV monoinfection and dual infection with HIV. Given the heightened incidence of HCV in injection drug users and men who have sex with men, the findings would support regular screening and early treatment in high-risk individuals.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Clinical Decision Making, Informatics, and Telemedicine, Department of MedicineTufts Medical CenterBostonUSA

Personalised recommendations